Our FocusDiagnostic Hybrids, Inc. (DHI) is engaged in the development, manufacture, and marketing of innovative cell culture products for various applications in diagnostic virology and endocrine disease. Our products are changing the way people view, and use, cell culture to address a wide variety of issues because they result in faster and cost-effective diagnosis of important disease states. Identification of viruses, identifying autoimmune antibodies in Graves Disease patients, and screening for new antiviral compounds are a few examples of the breadth of diagnostic applications our products reach.
Our Goal:
DHI optimizes the value its products provide to its clients by providing a "systems approach" in product design and format. For example, the ELVISŪ technology represents a sophisticated genetic engineering technology but is provided in a simple to use but highly sensitive and specific product format for the rapid, 1-day detection of herpes infections. All the materials required to perform the test are FDA cleared and supplied by DHI for optimal product performance.
Our Expectations
Cell culture technology, when developed to its fullest potential, will provide tangible benefits across many diagnostic venues. Specific near-term advances include linking genetic regulatory sequences to reporter genes to make specific gene-inducible events easily detected and cloning of analyte-specific receptors on cells to enhance the binding of ligands or viruses to mixing cells together to achieve an enhanced "nearest-neighbor" effect. Certainly, the future for cell culture in diagnostic virology is indeed a bright one as we continue to Advance Virology Through the Cell.
Manufacturing
Dedicated FDA inspected, cGMP manufacturing facility; proprietary manufacturing technologies for gene probes, cell culture, and multi-well plate products; NRC-licensed radiolabeling facility for the manufacture and distribution of radioisotopic detection kits; Manufacturer of fluorescent antibody kits.
Sales/Distribution
Established, effective direct sales and distribution infrastructure.
Business Partnerships
DHI offers it's products on a world wide basis through a growing network of international distributors.
History and Organization
DHI was founded in 1983 by successful biomedical entrepreneur Wilfred R. Konneker, Ph.D., in collaboration with Ohio University Professors Joseph Jollick, Ph.D., and Thomas E. Wagner, Ph.D., who led the OU research team that developed the world's first transgenic animal. The company is privately held. For current staff information, visit Meet the Staff
| Contact Details: |
| 350 West State St |
| Athens |
| Ohio |
| 45701 |
| United States of America |
| Tel: | (740) 593-1784 |
| Fax: | (740) 593-0980 |
| Email: | info@dhiusa.com |
| WWW: | www.dhiusa.com/
|
|
Loading...
|
Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 155 times since April 2007, the link to the organisation's website has been followed 34 times
Recent Search Terms used to find this page: Diagnostic Hybrids cloning | .
Search for more companies in Athens
Search for more companies in Ohio
This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for
Diagnostic Hybrids
